摘要
Half a year after its emergence, severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has resulted in a pandemic, with cases continuing to increase in nearly every country. Surges in coronavirus disease of 2019 (COVID-19) cases have clearly had profound effects on current cancer treatment paradigms. Considering the effect of antineoplastic treatment and the immunosuppressive properties of cancer itself, cancer patients are deemed to be more vulnerable to SARS-CoV-2. Hence, the specific risk of SARS-CoV-2 must be carefully weighed against the benefit of antineoplastic treatment for cancer patients in the COVID-19 era. In this review, we discuss the current evidence in this important field, and in particular, the effect of SARS-CoV-2 on antineoplastic treatment.
学科与关键词
- An Open Letter: COVID-19 and Cancer.Printz, CarrieCancer, 2021, 127(8): 1171.
- 2019-nCoV-SARS-CoV-2 (COVID-19) infection: Crucıalıty of Furın and relevance wıth cancerCigdem Usul AfsarMedical Hypotheses, 2020, 140: 109770.
- New Normal for Lung Cancer Clinical Trials Under Coronavirus Disease 2019Zhang, Chao; Wu, Yi-Long; Zhong, Wen-Zhao*Journal of Thoracic Oncology, 2022, 17(5): 588-591.被引 1
